We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Mr. Bliss has spent most of his career commercializing technology and research. Prior to Genisphere, he was the founding Chief Executive Officer at TheraKine, a start-up, biophysical matrix, sustained-release, drug delivery technology company. Previously, he managed licensing, corporate development and business development departments at Amgen and Baxter. At Amgen, Mr. Bliss managed Corporate Development during the acquisition of Abgenix. He went on to manage three departments within the Licensing/R&D organization, International Licensing, Licensing Operations and China/India R&D activities, the latter of which he created under Dr. Roger Perlmutter's direction from concept to include over 200 R&D staff members across five departments. While at Baxter, Mr. Bliss completed over 16 licensing agreements including antibody agreements with Dyax and Protein Design Labs, and a commercialization agreement with InterMune
This speaker's sessions: